Fauci says pausing vaccine trial for safety review is "not uncommon at all" - 2020-09-09
Anthony Fauci said on Wednesday that it's "not uncommon at all" for a vaccine maker to pause its trials to review safety concerns, following news that AstraZeneca had done so on its phase 3 coronavirus vaccine trials due to a participant having a severe adverse reaction.
Driving the news: AstraZeneca, one of the frontrunners in the global race for a COVID-19 vaccine, said on Tuesday that the patient is expected to recover but did not make clear what the reaction was.
"In large trials illnesses will happen by chance but must be independently reviewed to check this carefully. We are working to expedite the review of the single event to minimize any potential impact on the trial timeline," the company said in a statement.